Pharmacoeconomic Systematic Review of Osimertinib for Advanced Non-small Cell Lung Cancer
- VernacularTitle:奥希替尼治疗晚期非小细胞肺癌的药物经济学系统评价
- Author:
Xue MI
1
;
Xuelong SU
2
,
3
;
Weihong SUN
4
;
Jiameng LI
1
;
Hua GAO
4
Author Information
1. School of Pharmacy，Ningxia Medical University，Yinchuan 750004，China
2. Clinical Research Center of Shaanxi Province for Dental and Maxillofacial Diseases，College of Stomatology，Xi’an Jiaotong University，Xi’an 710004，China
3. Dept. of Pediatric Dentistry，Stomatological Hospital，Xi’an Jiaotong University，Xi’an 710004，China
4. Dept. of Pharmacy，General Hospital o f Ningxia Medical University，Yinchuan 750004，China
- Publication Type:Journal Article
- Keywords:
Osimertinib;
Advanced non-small cell lung cancers;
Cost-effectiveness analysis;
Systematic re view
- From:
China Pharmacy
2021;32(6):713-719
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To s ystematically review the economics of osimertinib for advanced non-small cell lung cancer （NSCLC），and to provide the reference for clinical application and healthcare decision makers. METHODS ：Retrieved from PubMed，Embase，the Cochrane L ibrary，Health Technology Assessment ，CNKI，Wanfang database ，VIP，CBM，etc.， pharmacoeconomic studies on osimertinib in the treatment of advanced NSCLC were collected from the inception to Apr. 2020. After screening and extracting relevant data ，the quality of the included studies was evaluated by using the Quality of Health Economics Studies （QHES），and the economic research results of the included literatures were systematically evaluated by using descriptive analysis method. RESULTS & CONCLUSIONS ：A total of 10 studies from 7 different countries were included ；QHES scores of the included literatures were 73-93，with an average of 86.8，and the quality of the researches was generally high. All the 10 studies were cost-effectiveness analysis ，including 6 first-line treatment ，4 second-line treatment. Six studies reported the cost discount rate ；only one study used the cost of osimertinib after price reduction for evaluation and analysis. Compared with other epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKI），six studies from different countries showed that osimertinib as the first-line treatment drug had no cost-effectiveness advantage ；cost-effectiveness of second-line treatment of osimertinib was controversial ，compared to chemotherapy. For advanced NSCLC patients ，the second-line treatment of osimertinib after the national centralized negotiation of price reduction has a more cost-effectiveness advantage in China ’s medical service system，while the first-line treatment of osimertinib before price reduction does not have this advantage compared with other EGFR-TKI drugs.
